Please use this identifier to cite or link to this item:
|Title:||Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest|
Bill Walsh Cancer Research Laboratories
|Keywords:||H69CIS200 cell line|
H69OX400 cell line
|Citation:||Stordal B, Davey, R. Regrowth Resistance: Low-Level Platinum Resistance Mediated by Rapid Recovery from Platinum-Induced Cell-Cycle Arrest. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Humana Press. 2009. p.171-6.|
|Abstract:||The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small-cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin and 400 ng/ml oxaliplatin, respectively. A recovery period was given between treatments to emulate the cycles of chemotherapy given in the clinic. The resistant cell lines were approximately twofold resistant to cisplatin and oxaliplatin, and were cross-resistant to both drugs. Platinum resistance was not associated with increased cellular glutathione, decreased accumulation of platinum or increased DNA repair capacity. The H69 platinum sensitive cells entered a lengthy 3-week growth arrest in response to low-level cisplatin or oxaliplatin treatment. This is an example of the coordinated response between the cell cycle and DNA repair. In contrast, the H69CIS200 and H69OX400 cells have an alteration in the cell cycle allowing them to rapidly proliferate post drug treatment. The resistant cell lines also have many chromosomal rearrangements most of which are not associated with the resistant phenotype, suggesting an increase in the genomic instability in the resistant cell lines. We hypothesized that there was a lack of coordination between the cell cycle and DNA repair in the resistant cell lines allowing proliferation in the presence of DNA damage which has created an increase in genomic instability. The H69 cells and resistant cell lines have mutant p53 and consequently decrease the expression of p21 in response to platinum drug treatment; promoting progression of the cell cycle instead of increasing p21 to maintain the arrest. A decrease in ERCC1 protein expression and an increase in RAD51B foci activity were observed with the platinum-induced cell-cycle arrest and did not correlate with resistance or altered DNA repair capacity. These changes may, in part, be mediating and maintaining the cell-cycle arrest in place of p21.The rapidly proliferating resistant cells have restored the levels of both these proteins to their levels in untreated cells. We use the term “regrowth resistance” to describe this low-level platinum resistance where cells survive treatment through increased proliferation. Regrowth resistance may play a role in the onset of clinical resistance.|
|Department/Unit/Centre:||Bill Walsh Cancer Research Laboratories|
|Rights and Permissions:||The University of Sydney claims copyright ownership of all information stored on this site, unless expressly stated otherwise.|
|Type of Work:||Book chapter|
|Appears in Collections:||Research Papers and Publications. NCS Medicine|
This work is protected by Copyright. All rights reserved. Access to this work is provided for the purposes of personal research and study. Except where permitted under the Copyright Act 1968, this work must not be copied or communicated to others without the express permission of the copyright owner. Use the persistent URI in this record to enable others to access this work.
|2009-Stordal-ISPCC-RegrowthResistance.pdf||285.42 kB||Adobe PDF||View/Open|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.